Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyAtezolizumab with Neoadjuvant Anti–HER2 Therapy and Chemotherapy in HER2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

The IMpassion050 study was the first to assess the question: Can addition of atezolizumab to neoadjuvant standard of care (pertuzumab and trastuzumab [PH], and chemotherapy) improve outcomes in high-risk, HER2–positive early breast cancer? The results are a click away.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form